



-hospital cardiac arrest. *Am J Cardiol* 2006; 358(9276): 105–109.

22. Goldsmith SR. Baroreceptor-mediated suppression of osmotically stimulated vasopressin in normal humans. *J Appl Physiol* 1988; 65: 1226–1230.

23. Prengel AW, Lindner KH, Keller A. Cerebral oxygenation during cardiopulmonary resuscitation with epinephrine and vasopressin in pigs. *Stroke* 1996; 27: 1241–1248.

24. Fox AW, May RE, Mitch WE. Comparison of peptide and nonpeptide receptormediated responses in rat tail artery. *J Cardiovasc Pharmacol* 1992; 20: 282–289.

25. Currigan DA, Hughes RJ, Wright CE, Angus JA, Soeding PF. Vasoconstrictor responses to vasopressor agents in human pulmonary and radial arteries: an in vitro study. *Anesthesiology* 2014; 121: 930–936.

26. den Ouden DT, Meinders AE. Vasopressin: physiology and clinical use in patients with vasodilatory shock: a review. *Neth J Med* 2005; 63: 4–13.

27. Mulligan KA, McKnite SH, Lindner KH, Lindstrom PJ, Detloff B, Lurie KG. Synergistic effects of vasopressin plus epinephrine during cardiopulmonary resuscitation. *Resuscitation* 1997; 35: 265–271.

28. Ullian ME. The role of corticosteroids in the regulation of vascular tone. *Cardiovasc Res* 1999; 41: 55–64.

29. Lindner KH, Strohmenger HU, Ensinger H, Hetzel WD, Ahnefeld FW, Georgieff M. Stress hormone response during and after cardiopulmonary resuscitation. *Anesthesiology* 1992; 77: 662–668.

30. Wenzel V. A comparison of vasopressin and epinephrine for out-of-hospital cardiopulmonary resuscitation. *N Engl J Med* 2004; 350(2): 105–113.

31. Turner DW. Vasopressin associated with an increase in return of spontaneous circulation in acidotic cardiopulmonary arrest patients. *Ann Pharmacother*; 2014; 48(8): 986–991.

32. Roden DM. Antiarrhythmic drugs: from mechanisms to clinical practice. *Heart* 2000; 84: 339–346.

33. Myerburg RJ, Castellanos A. Therapy for cardiac arrhythmias. In Bonow RO, ed. *Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine*. 9th ed. Philadelphia: Elsevier Saunders; 2012: 710.

34. Van Herendael H, Dorian P. Amiodarone for the treatment and prevention of ventricular fibrillation and ventricular tachycardia. *Vasc Health Risk Manag* 2010; 6: 465–472.

35. Huang J. The effects of acute and chronic amiodarone on activation patterns and defibrillation threshold during ventricular fibrillation in dogs. *J Am Coll Cardiol*; 2002; 40(2): 375–383.

36. Kudenchuk PJ. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. *N Engl J Med* 1999; 341(12): 871–878.

37. Dorian P. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. *N Engl J Med*; 2002; 346(12): 884–890.

38. Pollak PT, Wee V, Al-Hazmi A, Martin J, Zarnke KB. The use of amiodarone for in-hospital cardiac arrest at two tertiary care centres. *Can J Cardiol* 2006; 22: 199–202.

39. Rea RS, Kane-Gill SL, Rudis MI, Seybert AL, Oyen LJ, Ou NN, Stauss JL, Kirisci L, Idrees U, Henderson SO. Comparing intravenous amiodarone or lidocaine, or both, outcomes for inpatients with pulseless ventricular arrhythmias. *Crit Care Med* 2006; 34: 1617–1623.

40. Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure. A Bayesian meta-analysis. *Ann Intern Med* 2001; 134: 550.

41. Zhang Q, Li C. Combination of epinephrine with esmolol attenuates postresuscitation myocardial dysfunction in a porcine model of cardiac arrest. *PLoS ONE* 2013; 8: e82677.

42. Driver BE, Debaty G, Plummer DW, Smith SW. Use of esmolol after failure of standard cardiopulmonary resuscitation to treat patients with refractory ventricular fibrillation. *Resuscitation* 2014; 85: 1337–1341.

43. Varvarousi G, Stefaniotou A, Varvaroussis D, Xanthos T. Glucocorticoids as an emerging pharmacologic agent for cardiopulmonary resuscitation. *Cardiovasc Drugs Ther* 2014; 28: 477–488.

44. Smithline H, Rivers E, Appleton T, Nowak R. Corticosteroid supplementation during cardiac arrest in rats. *Resuscitation* 1993; 25: 257–264.

45. Tavakoli N, Bidari A, Shams Vahdati S. Serum cortisol levels as a predictor of neurologic survival in successfully resuscitated victims of cardiopulmonary arrest. *J Cardiovasc Thorac Res* 2012; 4: 107–111.

46. Tsai MS, Huang CH, Chang WT. The effect of hydrocortisone on the outcome of out-of-hospital cardiac arrest patients: a pilot study. *Am J Emerg Med* 2007; 25: 318–325.

47. Mentzelopoulos SD, Malachias S, Chamos C. Vasopressin, steroids, and epinephrine and neurologically favorable survival after in-hospital cardiac arrest: a randomized clinical trial. *JAMA* 2013; 310: 270–279.

48. Brown CG, Griffith RF, Neely D, Hobson J, Miller B. The effect of intravenous magnesium administration on aortic, right atrial and coronary perfusion pressures during CPR in swine. *Resuscitation* 1993; 26: 3–12.

49. Keller PK, Aronson RS. The role of magnesium in cardiac arrhythmias. *Prog Cardiovasc Dis* 1990; 32: 433–448.

50. Chen F, Lin Q, Chen G. Does intravenous magnesium benefit patients of cardiac arrest? A meta-analysis. *Hong Kong J Emerg Med* 2012; 19: 103–109.

51. Morton HJ, Thomas ET. Effect of atropine on the heart-rate. *Lancet* 1958; 2: 1313–131.

52. DeBehnke DJ, Swart GL, Spreng D, Aufderheide TP. Standard and higher doses of atropine in a canine model of pulseless electrical activity. *Acad Emerg Med* 1995; 2: 1034–1041.

53. Nagao K, Yagi T, Sakamoto T, et al. Atropine sulfate for patients with out-of-hospital cardiac arrest. *N Engl J Med*; 2002; 346(12): 884–890.